Updated hourlyHourly refreshTue, Oct 27, 2026
Press Release Database
Recent press releases, indexed by topic.
Finance · Biotech & pharma
NEW YORK, Oct. 02, 2026 --
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the “Class Period”), of the important November 2, 2026 lead plaintiff deadline.
Oct 2 · 23:34·GlobeNewswire
Healthcare · Biotech & pharma
Stanley Clarke recalls how jazz legend Chick Corea helped him step away from drugs and introduced him to Dianetics: The Modern Science of Mental Health.
Oct 2 · 22:45·GlobeNewswire
Biotech & pharma
The proprietary program targets a lactate–autophagy pathway to reactivate quiescent hair follicle stem cells. In a mouse model, a candidate achieved a hair-growth score comparable to that of 5% topical minoxidil at just 1/100 of the comparator's concentration. The milestone builds on the...
Oct 2 · 22:33·PR Newswire
Finance · Energy
BOCA RATON, Fla., Oct. 02, 2026 -- NOMAD Power Solutions, Inc. ("NOMAD" or the "Company") (Nasdaq: NMAD) (formerly LIXTE Biotechnology Holdings), a provider of transportable, utility-grade battery energy storage systems through its wholly owned subsidiary NOMAD Transportable Power Systems, today announced that its Special Meeting of Stockholders (the “Special Meeting”), reconvened on October 2, 2026, was adjourned without conducting any business. The Special Meeting will reconvene on October 30, 2026, at 1:00 PM Eastern Time.
Oct 2 · 22:23·GlobeNewswire
Finance · Biotech & pharma
New York, New York--(October 2, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline.SO WHAT: If you purchased Unicycive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs...
Oct 2 · 22:17·Newsfile
Finance · Biotech & pharma
NEW YORK, Oct. 2, 2026 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the "Class Period"), of the important October 5, 2026 lead plaintiff...
Oct 2 · 22:01·PR Newswire
Healthcare · Food & drink
Bagsværd, Denmark, 02 October 2026 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has informed Novo that the BLA review of denecimig for the treatment of haemophilia A, with or without inhibitors in adults and children, is still ongoing. The FDA has not communicated a new timeline for expected regulatory action on the BLA.
Oct 2 · 20:53·GlobeNewswire
Finance · Biotech & pharma
NEW YORK, Oct. 2, 2026 -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration...
Oct 2 · 20:44·PR Newswire
Finance · Healthcare
SAN FRANCISCO, Oct. 02, 2026 -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to six new employees to purchase an aggregate of 235,950 shares of the Company's common stock, effective as of October 1, 2026. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
Oct 2 · 20:30·GlobeNewswire
Finance · Healthcare
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 02, 2026 -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on October 1, 2026 (the “Grant Date”), ORIC granted a total of 161,550 non-qualified stock options and 26,850 restricted stock units to six new non-executive employees who began their employment with ORIC in September 2026.
Oct 2 · 20:30·GlobeNewswire
Finance · Biotech & pharma
RADNOR, Pa., Oct. 02, 2026 -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, today announced that new data from the Launch-HTN trial of lorundrostat will be presented at the American Society of Nephrology Kidney Week 2026, taking place October 21-25 in Denver, Colorado.
Oct 2 · 20:30·GlobeNewswire
Finance · Healthcare
WALTHAM, Mass., Oct. 02, 2026 -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective October 1, 2026, the company granted non-qualified stock options to purchase an aggregate of 100,895 shares of its common stock to two new employees under Xilio Therapeutics’ Third Amended and Restated 2022 Inducement Stock Incentive Plan (the 2022 Inducement Stock Incentive Plan). Additionally, the company granted a non-qualified stock option to purchase 105,000 shares of its common stock under the 2022 Inducement Stock Incentive Plan to the company’s newly appointed Chief Medical Officer, Yariv Houvras, M.D., Ph.D.
Oct 2 · 20:30·GlobeNewswire